Skip to main content

Table 1 Characteristics of included studies

From: Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis

Study

Design

NOS

Group

Sample size

Tumor size, cm

Number of tumor S/M

Tumor differentiation well/moderately/poorly

Surgical margin N/P

Portal vein invasion yes/no

MVI yes/no

median OS (month)

median DFS (month)

Chemotherapy

Nomami

R

6

LR + HAIC

19

NA

NA

NA

NA

NA

NA

NA

NA

5-FU + DO + MI

1991 Japan

  

LR alone

113

NA

NA

NA

NA

NA

NA

NA

NA

 

Kim

R

7

LR + HAIC

31

4.8 ± 2.3

29/2

0/10/14

8/23

11/20

25/6

NR

10.5

5-FU + CI

2011 Korea

  

LR alone

62

4.3 ± 2.4

60/2

1/20/34

23/39

13/49

43/19

NR

7.5

 

Kumatoto

R

9

LR + HAIC

16

7.61 ± 4.34

NA

NA

NA

16/0

NA

55.3

12.2

5‐FU + Interferon

2013 Japan

  

LR alone

17

9.48 ± 6.54

NA

NA

NA

12/5

NA

16.1

6.9

 

Nagano

R

7

LR + HAIC

30

NA

NA

NA

NA

30/0

NA

36.5

29

5‐FU + Interferon

2013 Japan

  

LR alone

20

NA

NA

NA

NA

20/0

NA

8.5

5.5

 

Nitta

R

8

LR + HAIC

38

6.66 ± 3.93

13/25

14/23/1

33/5

38/0

NA

55

13

5-FU + CI/5-FU + CI + MI

2013 Japan

  

LR alone

35

7.00 ± 4.23

12/23

22/12/1

32/3

35/0

NA

26

7

 

Kojima

R

9

LR + HAIC

27

7.0 (2.8–18.0)

10/17

1/12/12

19/8

27/0

NA

33.2

12.4

5-FU + CI + EP

2015 Japan

  

LR alone

25

5.0 (1.4–17.0)

8/17

3/9/12

19/6

25/0

NA

21.5

6.2

 

Feng

R

9

LR + HAIC

42

6.2 ± 1.5

24/18

10/12/20

NA

0/42

28/14

51.1

42.2

5-FU + OX + MI

2017 China

  

LR alone

43

5.7 ± 1.3

23/20

12/14/17

NA

0/43

25/18

32.8

22.1

 

Hsiao

R

7

LR + HAIC

61

20(<= 5 cm) 41(> 5 cm)

33/28

0/16/45

33(< 10 mm) 28 (≥ 10 mm)

0/61

NA

56.4

50.6

5-FU + CI + LE + EP

2017 China

  

LR alone

160

81(<= 5 cm) 79(> 5 cm)

81/79

0/56/104

121(< 10 mm) 39 (≥ 10 mm)

0/160

NA

56.9

54.5

 

Hamada

R

7

LR + HAIC

37

5.4 ± 3.6

NA

7/30 (well/other)

NA

37/0

37/0

NR

22.7

CI

2020 Japan

  

LR alone

85

5.7 ± 3.7

NA

17/68 (well/other)

NA

52/33

62/23

NR

10.5

 

Hirokawa

RCT

/

LR + HAIC

55

3.4 (1.0–14.5)

41/14

46/9 (other/poorly)

5 (0–32) mm

0/55

14/41

NR

44.9

CI + LI

2020 Japan

  

LR alone

59

3.1 (1.0–12)

51/8

14/45 (other/poorly)

5 (0–36) mm

0/59

11/48

NR

35

 

Li

RCT

/

LR + HAIC

157

5.6 (1.8–30.0)

114/45

4/59/92

NA

0/157

157/0

NR

20.3

FOLFOX

2022 China

  

LR alone

158

5.4 (1.5–16.0)

128/30

2/76/80

NA

0/158

158/0

NR

10.0

 
  1. R retrospective study, RCT randomized controlled trial, NOS Newcastle–Ottawa Scale, LR hepatic resection, HAIC hepatic artery infusion chemotherapy, NA not available, NR not reached, S solitary, M multiple, N negative, P positive, MVI microvascular invasion, OS overall survival, DFS disease-free survival, 5-FU 5-fluoruracil, DO doxorubicin, CI cisplatin, OX oxaliplatin, MI mitomycin-C, LE Leucovorin, EP Epirubicin, LI Lipiodol